Where can I find 300294.SZ's financial statements?

China Resources Boya Bio-pharmaceutical Group Co., Ltd. (300294.SZ)'s full income statement, balance sheet, and cash flow statement are on this page in 10-K-style line-item format. Switch between the three statements via the pill toggle above the table.

How much history is available for 300294.SZ?

China Resources Boya Bio-pharmaceutical Group Co., Ltd. (300294.SZ) statements are available back to its earliest filed 10-K — typically 10+ years of annual data and 40 quarters of quarterly data. Free-tier users see 5 years and 8 quarters; full history unlocks with a Pro account.

How often does 300294.SZ update its statements?

China Resources Boya Bio-pharmaceutical Group Co., Ltd. files a 10-K annually (full audited year-end statements) and 10-Q reports quarterly (unaudited interim statements). New filings are typically parsed and reflected on this page within 48 hours of SEC submission.

300294.SZ

China Resources Boya Bio-pharmaceutical Group Co., Ltd.

SHZ·Biotechnology · Healthcare

¥15.08¥0.19+1.28%

Market cap¥7.60B·Market closed·Aug 26 7:04 AM UTC

CNY · values shown as reported

Line item	FY 2021	FY 2022	FY 2023	FY 2024	FY 2025
Revenue	¥2.65B+5.5%	¥2.76B+4.1%	¥2.65B−3.9%	¥1.73B−34.6%	¥2.05B+18.2%
Cost of revenue	¥1.19B+12.5%	¥1.25B+5.7%	¥1.26B+0.3%	¥615.97M−51.1%	¥1.11B+80.7%
Gross profit	¥1.46B+0.4%	¥1.50B+2.8%	¥1.39B−7.4%	¥1.12B−19.7%	¥936.88M−16.3%
Research & development	¥59.29M−34.6%	¥49.58M−16.4%	¥67.70M+36.5%	¥71.35M+5.4%	¥50.74M−28.9%
General & administrative	¥199.17M+15.4%	¥226.37M+13.7%	¥189.54M−16.3%	¥180.81M−4.6%	¥598.11M+230.8%
Selling & marketing	¥769.68M−11.0%	¥697.27M−9.4%	¥585.17M−16.1%	¥422.85M−27.7%	—
SG&A (combined)	¥968.84M−6.6%	¥923.64M−4.7%	¥774.71M−16.1%	¥603.65M−22.1%	¥598.11M−0.9%
Other operating expenses	−¥7.85M−275.7%	−¥1.38M+82.4%	¥195.66M+14,250.9%	−¥33.33M−117.0%	¥18.36M+155.1%
Total operating expenses	¥1.02B−9.4%	¥971.84M−4.7%	¥1.04B+6.8%	¥641.68M−38.2%	¥667.21M+4.0%
Operating income	¥443.06M+33.7%	¥532.18M+20.1%	¥355.23M−33.3%	¥477.25M+34.4%	¥269.66M−43.5%
Interest income	¥31.50M+115.2%	¥26.20M−16.8%	¥31.29M+19.4%	¥29.43M−6.0%	¥13.62M−53.7%
Interest expense	¥10.53M−51.9%	¥922.07K−91.2%	¥800.54K−13.2%	¥1.09M+36.1%	¥1.56M+43.6%
Other income / (expense), net	¥61.40K+101.8%	−¥179.00K−391.6%	−¥1.51M−745.4%	¥458.82K+130.3%	−¥165.79M−36,233.1%
Income before tax	¥443.12M+35.0%	¥532.00M+20.1%	¥353.71M−33.5%	¥477.71M+35.1%	¥103.88M−78.3%
Income tax expense	¥84.84M+60.5%	¥86.51M+2.0%	¥105.56M+22.0%	¥81.19M−23.1%	−¥8.76M−110.8%
Net income	¥344.53M+32.5%	¥432.20M+25.4%	¥237.47M−45.1%	¥396.99M+67.2%	¥112.70M−71.6%

EPS (basic)	¥0.79+29.5%	¥0.86+8.9%	¥0.47−45.3%	¥0.79+68.1%	¥0.22−72.2%
EPS (diluted)	¥0.79+29.5%	¥0.86+8.9%	¥0.47−45.3%	¥0.79+68.1%	¥0.22−72.2%
Weighted avg shares (basic)	436,112,657	504,248,738	505,245,944	504,248,738	504,248,738
Weighted avg shares (diluted)	436,112,657	504,248,738	505,245,944	504,248,738	504,248,738

Depreciation & amortization	¥96.16M+18.2%	¥93.22M−3.1%	¥94.99M+1.9%	¥97.71M+2.9%	¥164.69M+68.5%
EBITDA	¥510.65M+24.1%	¥600.38M+17.6%	¥624.38M+4.0%	¥519.84M−16.7%	¥270.13M−48.0%

Frequently Asked Questions About 300294.SZ

Where can I find 300294.SZ's financial statements?: China Resources Boya Bio-pharmaceutical Group Co., Ltd. (300294.SZ)'s full income statement, balance sheet, and cash flow statement are on this page in 10-K-style line-item format. Switch between the three statements via the pill toggle above the table.
How much history is available for 300294.SZ?: China Resources Boya Bio-pharmaceutical Group Co., Ltd. (300294.SZ) statements are available back to its earliest filed 10-K — typically 10+ years of annual data and 40 quarters of quarterly data. Free-tier users see 5 years and 8 quarters; full history unlocks with a Pro account.
How often does 300294.SZ update its statements?: China Resources Boya Bio-pharmaceutical Group Co., Ltd. files a 10-K annually (full audited year-end statements) and 10-Q reports quarterly (unaudited interim statements). New filings are typically parsed and reflected on this page within 48 hours of SEC submission.

Line item

FY 2021

FY 2022

FY 2023

FY 2024

FY 2025

Trend

Revenue

¥2.65B+5.5%

¥2.76B+4.1%

¥2.65B−3.9%

¥1.73B−34.6%

¥2.05B+18.2%

Cost of revenue

¥1.19B+12.5%

¥1.25B+5.7%

¥1.26B+0.3%

¥615.97M−51.1%

¥1.11B+80.7%

Gross profit

¥1.46B+0.4%

¥1.50B+2.8%

¥1.39B−7.4%

¥1.12B−19.7%

¥936.88M−16.3%

Research & development

¥59.29M−34.6%

¥49.58M−16.4%

¥67.70M+36.5%

¥71.35M+5.4%

¥50.74M−28.9%

General & administrative

¥199.17M+15.4%

¥226.37M+13.7%

¥189.54M−16.3%

¥180.81M−4.6%

¥598.11M+230.8%

Selling & marketing

¥769.68M−11.0%

¥697.27M−9.4%

¥585.17M−16.1%

¥422.85M−27.7%

—

SG&A (combined)

¥968.84M−6.6%

¥923.64M−4.7%

¥774.71M−16.1%

¥603.65M−22.1%

¥598.11M−0.9%

Other operating expenses

−¥7.85M−275.7%

−¥1.38M+82.4%

¥195.66M+14,250.9%

−¥33.33M−117.0%

¥18.36M+155.1%

Total operating expenses

¥1.02B−9.4%

¥971.84M−4.7%

¥1.04B+6.8%

¥641.68M−38.2%

¥667.21M+4.0%

Operating income

¥443.06M+33.7%

¥532.18M+20.1%

¥355.23M−33.3%

¥477.25M+34.4%

¥269.66M−43.5%

Interest income

¥31.50M+115.2%

¥26.20M−16.8%

¥31.29M+19.4%

¥29.43M−6.0%

¥13.62M−53.7%

Interest expense

¥10.53M−51.9%

¥922.07K−91.2%

¥800.54K−13.2%

¥1.09M+36.1%

¥1.56M+43.6%

Other income / (expense), net

¥61.40K+101.8%

−¥179.00K−391.6%

−¥1.51M−745.4%

¥458.82K+130.3%

−¥165.79M−36,233.1%

Income before tax

¥443.12M+35.0%

¥532.00M+20.1%

¥353.71M−33.5%

¥477.71M+35.1%

¥103.88M−78.3%

Income tax expense

¥84.84M+60.5%

¥86.51M+2.0%

¥105.56M+22.0%

¥81.19M−23.1%

−¥8.76M−110.8%

Net income

¥344.53M+32.5%

¥432.20M+25.4%

¥237.47M−45.1%

¥396.99M+67.2%

¥112.70M−71.6%

EPS (basic)

¥0.79+29.5%

¥0.86+8.9%

¥0.47−45.3%

¥0.79+68.1%

¥0.22−72.2%

EPS (diluted)

¥0.79+29.5%

¥0.86+8.9%

¥0.47−45.3%

¥0.79+68.1%

¥0.22−72.2%

Weighted avg shares (basic)

436,112,657

504,248,738

505,245,944

504,248,738

Weighted avg shares (diluted)

436,112,657

504,248,738

505,245,944

504,248,738

Depreciation & amortization

¥96.16M+18.2%

¥93.22M−3.1%

¥94.99M+1.9%

¥97.71M+2.9%

¥164.69M+68.5%

EBITDA

¥510.65M+24.1%

¥600.38M+17.6%

¥624.38M+4.0%

¥519.84M−16.7%

¥270.13M−48.0%